334 related articles for article (PubMed ID: 32154170)
1. Association of
Jia M; Yao L; Yang Q; Chi T
Front Oncol; 2020; 10():168. PubMed ID: 32154170
[TBL] [Abstract][Full Text] [Related]
2. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
3. Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
Li Y; Jiang W; Li T; Li M; Li X; Zhang Z; Zhang S; Liu Y; Zhao W; Gu Y; Qi L; Ao L; Guo Z
J Transl Med; 2020 Jan; 18(1):25. PubMed ID: 31937321
[TBL] [Abstract][Full Text] [Related]
4. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
[TBL] [Abstract][Full Text] [Related]
5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
6. MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma.
Lv Y; Huang Z; Lin Y; Fang Y; Chen Z; Pan L; Zhang Y; Xu Z
Oncoimmunology; 2019; 8(10):e1629260. PubMed ID: 31646073
[No Abstract] [Full Text] [Related]
7. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments.
Wang C; Lu T; Xu R; Chang X; Luo S; Peng B; Wang J; Yao L; Wang K; Shen Z; Zhao J; Zhang L
J Thorac Dis; 2022 Jun; 14(6):2131-2146. PubMed ID: 35813746
[TBL] [Abstract][Full Text] [Related]
8. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
[TBL] [Abstract][Full Text] [Related]
9. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.
He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD
Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103
[TBL] [Abstract][Full Text] [Related]
10. Identification of CNKSR1 as a biomarker for "cold" tumor microenvironment in lung adenocarcinoma: An integrative analysis based on a novel workflow.
Cai Q; Peng M
Heliyon; 2024 Apr; 10(8):e29126. PubMed ID: 38628722
[TBL] [Abstract][Full Text] [Related]
11. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
[TBL] [Abstract][Full Text] [Related]
12. Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma.
Peng J; Zou D; Gong W; Kang S; Han L
Oncoimmunology; 2020; 9(1):1734156. PubMed ID: 32158626
[TBL] [Abstract][Full Text] [Related]
13. RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma.
Liu B; Wang Y; Wang H; Li Z; Yang L; Yan S; Yang X; Ma Y; Gao X; Guan Y; Yi X; Xia X; Li J; Wu N
Front Oncol; 2021; 11():677826. PubMed ID: 34367963
[TBL] [Abstract][Full Text] [Related]
14. Optimizing panel-based tumor mutational burden (TMB) measurement.
Budczies J; Allgäuer M; Litchfield K; Rempel E; Christopoulos P; Kazdal D; Endris V; Thomas M; Fröhling S; Peters S; Swanton C; Schirmacher P; Stenzinger A
Ann Oncol; 2019 Sep; 30(9):1496-1506. PubMed ID: 31268125
[TBL] [Abstract][Full Text] [Related]
15. Correlation of tumor mutational burden with prognosis and immune infiltration in lung adenocarcinoma.
Li L; Li J
Front Oncol; 2023; 13():1128785. PubMed ID: 36959799
[TBL] [Abstract][Full Text] [Related]
16. Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients.
Wang Z; Wang C; Lin S; Yu X
Front Oncol; 2021; 11():725292. PubMed ID: 34513703
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
18. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
[TBL] [Abstract][Full Text] [Related]
19. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy.
Wang Q; Li M; Yang M; Yang Y; Song F; Zhang W; Li X; Chen K
Aging (Albany NY); 2020 Feb; 12(4):3312-3339. PubMed ID: 32091408
[TBL] [Abstract][Full Text] [Related]
20. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]